European Vascular Center Aachen-Maastricht, Department of Vascular Surgery, Aachen University Hospital, Aachen, Germany.
Dtsch Arztebl Int. 2013 Feb;110(8):119-25. doi: 10.3238/arztebl.2013.0119. Epub 2013 Feb 22.
The endovascular treatment of abdominal aortic aneurysms has become more common. A careful comparison of this technique with the established treatment by open surgery is needed before it can be more widely adopted.
We selectively searched the Medline database for articles on the endovascular treatment of abdominal aortic aneurysms, with special attention to prospective, randomized trials comparing it to open aortic surgery (keywords: "endovascular abdominal aortic repair" and "prospective randomized trial").
Data on 30-day mortality and long-term survival are now available from four randomized multicenter trials. In three of these trials, endovascular treatment was found to lower 30-day mortality by two-thirds (endovascular: 0.2% to 1.7%, open repair: 0.7% to 4.7%), but this difference in survival was no longer present at two years. Compared to open open aortic surgery, endovascular treatment has a higher long-term complication rate. Endoleakage (perigraft leakage) accounted for more than 30% of complications and was the commonest reason for reintervention and unsuccessful intervention; in nearly all cases, it was successfully treated by the endovascular route. The rate of secondary aortic rupture was 0.8%, and migration of the prosthesis occurred in 5% of cases. Follow-up checks of the stent graft are now recommended at 3, 6 and 12 months after implantation, and annually thereafter.
Prospective randomized trials have shown that the endovascular technique lowers perioperative mortality. In the long term, however, it has a higher complication rate than open aortic surgery and leads to more frequent reintervention.
腹主动脉瘤的血管内治疗变得更为常见。在更广泛地采用这种技术之前,需要对其与传统的开放性手术治疗进行仔细比较。
我们专门在 Medline 数据库中检索了关于腹主动脉瘤血管内治疗的文章,特别关注将其与开放性主动脉手术进行前瞻性随机对照试验的文章(关键词:“血管内腹主动脉修复”和“前瞻性随机试验”)。
目前已有四项随机多中心试验提供了 30 天死亡率和长期生存的数据。在这三项试验中,血管内治疗将 30 天死亡率降低了三分之二(血管内治疗:0.2%至 1.7%,开放性修复:0.7%至 4.7%),但两年后生存率的差异不再存在。与开放性主动脉手术相比,血管内治疗的长期并发症发生率更高。内漏(支架周围漏)占并发症的 30%以上,是再次干预和治疗失败的最常见原因;几乎所有情况下都可以通过血管内途径成功治疗。二次主动脉破裂的发生率为 0.8%,移植物迁移的发生率为 5%。建议在植入后 3、6 和 12 个月以及此后每年对支架移植物进行随访检查。
前瞻性随机试验表明,血管内技术可降低围手术期死亡率。然而,从长期来看,它的并发症发生率高于开放性主动脉手术,导致更频繁的再次干预。